Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Enanthate

FDA-approved product (injectable, injection), marketed as Delatestryl, Testosterone Enanthate, Xyosted (Autoinjector).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Enanthate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Enanthate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Enanthate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of 5-Alpha Reductase on Testosterone in Men

    NCT00070733 · start 2003-08

    Registered record
    Registry ID
    NCT00070733
    Conditions
    Sex Disorders
    Interventions
    testosterone enanthate; duastride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2003-08
    Completion
    2005-06
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSex Disorders
    Interventiontestosterone enanthate; duastride
    PhasePhase 3
    Registry statusUnknown

  • Testosterone and Physical Function in HIV+ Men

    NCT00260143 · start 2003-05

    Registered record
    Registry ID
    NCT00260143
    Conditions
    HIV Associate Weight Loss
    Interventions
    Testosterone enanthate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    2006-06
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Associate Weight Loss
    InterventionTestosterone enanthate; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency

    NCT00161304 · start 2003-04

    Registered record
    Registry ID
    NCT00161304
    Conditions
    Men With Low Testosterone Levels
    Interventions
    Testosterone Enanthate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2003-04
    Completion
    2004-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMen With Low Testosterone Levels
    InterventionTestosterone Enanthate; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Role of 5-alpha Reductase in Mediating Testosterone Actions

    NCT00493987 · start 2002-11

    Registered record
    Registry ID
    NCT00493987
    Conditions
    Healthy
    Interventions
    Testosterone Enanthate; Dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11
    Completion
    2010-03
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTestosterone Enanthate; Dutasteride
    PhasePhase 4
    Registry statusCompleted

  • A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

    NCT00001079

    Registered record
    Registry ID
    NCT00001079
    Conditions
    HIV Infections; HIV Wasting Syndrome
    Interventions
    Testosterone enanthate; Megestrol acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; HIV Wasting Syndrome
    InterventionTestosterone enanthate; Megestrol acetate
    PhasePhase 2
    Registry statusCompleted